To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism

Int J Mol Sci. 2023 Nov 3;24(21):15925. doi: 10.3390/ijms242115925.

Abstract

Many pathological conditions, including obesity, diabetes, hypertension, heart disease, and cancer, are associated with abnormal metabolic states. The progressive loss of metabolic control is commonly characterized by insulin resistance, atherogenic dyslipidemia, inflammation, central obesity, and hypertension, a cluster of metabolic dysregulations usually referred to as the "metabolic syndrome". Recently, nutraceuticals have gained attention for the generalized perception that natural substances may be synonymous with health and balance, thus becoming favorable candidates for the adjuvant treatment of metabolic dysregulations. Among nutraceutical proteins, lactoferrin (Lf), an iron-binding glycoprotein of the innate immune system, has been widely recognized for its multifaceted activities and high tolerance. As this review shows, Lf can exert a dual role in human metabolism, either boosting or resetting it under physiological and pathological conditions, respectively. Lf consumption is safe and is associated with several benefits for human health, including the promotion of oral and gastrointestinal homeostasis, control of glucose and lipid metabolism, reduction of systemic inflammation, and regulation of iron absorption and balance. Overall, Lf can be recommended as a promising natural, completely non-toxic adjuvant for application as a long-term prophylaxis in the therapy for metabolic disorders, such as insulin resistance/type II diabetes and the metabolic syndrome.

Keywords: glucose metabolism; iron metabolism; lactoferrin; lipid metabolism; metabolic syndrome.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic
  • Diabetes Mellitus, Type 2* / drug therapy
  • Energy Metabolism
  • Humans
  • Hypertension* / drug therapy
  • Inflammation / drug therapy
  • Insulin Resistance*
  • Iron / metabolism
  • Lactoferrin / metabolism
  • Metabolic Syndrome* / drug therapy
  • Obesity / drug therapy

Substances

  • Lactoferrin
  • Adjuvants, Immunologic
  • Iron

Grants and funding

This research received no external funding.